Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial
European Journal of Cancer, 06/29/2012
Clinical Article
Veal GJ et al. – The reduced pharmacokinetic variability and improved control of busulfan area under the plasma concentration versus time curve (AUC) observed following IV administration support its utility within the ongoing HR–NBL–1/SIOPEN trial.



